

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

6 Applicant is to place an "X" here if English language Translation is attached.

RECEIVED

TECH CENTER 1600/2900

SEP 14 2001

Substitute for form 1449A/PTO

SEP 10 2001

PATENT & TRADEMARK OFFICE

INFORMATION
DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2 Attorney Docket Number 35784/209112 (5784-50)

Complete if Known

Application Number	09/855,342
Filing Date	May 14, 2001
First Named Inventor	Caligiuri
Group Art Unit	54-1646 1642
Examiner Name	Not yet assigned

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
SR	3	DIERKSHEIDE <i>et al.</i> (1999) "Fc Receptor Cross-Linking in the Presence of Interleukin-12 is a Potent Stimulus to Natural Killer Production of Interferon-gamma: Implications for Anti-Her2 Antibody Therapy," <i>Proceedings of the American Association for Cancer Research</i> 40: 77 (XP002171956)	
	4	FLEMING <i>et al.</i> (1999) "Phase I Trial of Recombinant Human Anti-Her2 Monoclonal Antibody (H) Plus Low-Dose Interleukin-2 (IL-2) in Patients with Solid Tumors," <i>Proceedings of the Annual Meeting of the American Society for Clinical Oncology</i> 18: A710 (XP001010378)	
	5	KOPRESKI <i>et al.</i> (1996) "Growth Inhibition of Breast Cancer Cell Lines by Combinations of Anti-P185 ^{Her2} Monoclonal Antibody and Cytokines," <i>Anticancer Research</i> 16: 433-436 (XP000973070)	
	6	LI <i>et al.</i> (1999) "Preparation and Characterization of a Human Interleukin-2 and Anti-Human Her2 ScFv Fusion Protein," <i>Proceedings of the American Association for Cancer Research</i> 40: 358 (XP002171954)	
	7	LI <i>et al.</i> (2000) "Chemical Conjugation of a Novel Antibody-Interleukin 2 Immunoconjugate Against c-erbB-2 Product," <i>Chinese Medical Journal</i> 113: 151-153 (XP000925246)	
	8	TAGLIAFERRI <i>et al.</i> (1996) "Differential Sensitivity to Non-Major Histocompatibility Complex-Restricted Recombinant Interleukin 2-Activated Lymphocyte Killing of Human Mammary Epithelial MCF-10A Cells Overexpressing Oncogenes or Protein Kinase A Subunits," <i>Clinical Cancer Research</i> 2: 207-214 (XP002171953)	
SR	9	WEINER <i>et al.</i> (1995) "Clinical Development of 2B1, A Bispecific Murine Monoclonal Antibody Targeting c-erbB-2 and Fc-gamma-RIII," <i>Journal of Hematology</i> 4: 453-456 (XP002048529)	
SR	10	"Questions and Answers about NCI's Expanded Research with Herceptin (R)," <i>National Cancer Institute, Backgrounder, Online!</i> Bethesda, MD (September 28, 1998) URL: http://rex.nci.nih.gov/massmedia/back_pp_1-8 (XP002171955)	
		SR	

Examiner Signature	11	Date Considered	1/24/03
--------------------	----	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

Complete if Known

#6

INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

RECEIVED

SEP 26 2001

Attorney Docket Number

Caligiuri
1646 1642 TECH CENTER 1600/2900

5r

Not yet assigned

35784/209112 (5784-50)

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
SK	11	MEROPOL <i>et al.</i> (1996) "Daily Subcutaneous Injection of Low-Dose Interleukin 2 Expands Natural Killer Cells <i>in Vivo</i> Without Significant Toxicity," <i>Clin. Cancer Res.</i> 2: 669-677.					
SK	12	MEROPOL <i>et al.</i> (1998) "Evaluation of Natural Killer Cell Expansion and Activation <i>in Vivo</i> with Daily Subcutaneous Low-Dose Interleukin-2 Plus Periodic Intermediate-Dose Pulsing," <i>Cancer Immunol. Immunother.</i> 46: 318-326.					

Examiner Signature		Date Considered	1/24/03
--------------------	---	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2103788v1

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.